Ranitidine


Description

Ranitidine is a commonly used drug, classified as a _histamine H2-receptor antagonist_. This drug helps to prevent and treat gastric-acid related conditions, including ulcers, because of its ability to decrease gastric acid secretion [

Read more

Pharmacology

Indication

This drug is used alone or with concomitant antacids for the following conditions [FDA label]:

**...
Read more

Pharmacodynamic

Ranitidine decreases the secretion of gastric acid stimulated by food and drugs. It also reduces th... Read more

Mechanism of action

After a meal, the hormone gastrin, produced by cells in the lining of the stomach, stimulates the re... Read more

Absorption

Ranitidine is 50% absorbed after an oral tablet and both the syrup and effervescent tablet formulati... Read more

Protein binding

Approximately 15% [FDA label].

Volume of distribution

The volume of distribution is approximately 1.4 L/kg [FDA label].

Clearance

Renal clearance is 78 about 410 mL/min [FDA label]. Clearance is decreased in the elderly and those... Read more

Half life

2.5-3 hours [FDA label]. The plasma half-life is longer for elderly patients population due to a dec... Read more

Route of elimination

This drug is mainly excreted in the urine. About 30% of a single oral dose has been measured in the... Read more

Toxicity

**LD50**

Oral doses of 1,000 mg/kg in mice and rats were not found to be lethal. Intravenous LD50...
Read more


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Bronchospasm US
Pneumonia US
Rash US
Fever US
Erythema multiforme US
Rash US
Vasculitis US
Alopecia US
Loss of libido US
Impotence US
Gynecomastia US
Galactorrhea US
Marrow hypoplasia US
Pancytopenia US
Acquired immune hemolytic anemia US
Aplastic Anemia US
Increased SGPT US
Increases in serum creatinine US
Pain at site of IM injection US
Local burning at IM injection site US
Local itching at IM injection site US
Eosinophilia US
Anaphylaxis US
Angioneurotic Edema US
Acute Interstitial Nephritis US
Insomnia US
Vertigo US
Malaise US
Dizziness US
Depression US
Hallucinations US
Reversible mental confusion US
Agitation US
Arrhythmias US
Tachycardia US
Reversible blurred vision US
Reversible involuntary motor disturbances US
AV Block US
Premature Ventricular Beats US
Bradycardia US
Asystole US
Vomiting US
Nausea US
Diarrhea US
Constipation US
Hepatocellular hepatitis US
Pancreatitis US
Abdominal Pain US
Abdominal Discomfort US
Myalgia US

Contraindications

  • Regions: US
  • Patient Conditions:
      • Name: Known hypersensitivity to the drug or any of the ingredients
      • Drugbank Id: DBCOND0118758

Food Interactions

  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
  • Take without regard to meals.

Interactions

Type in a drug name to check for interaction with Ranitidine

The serum concentration of (R)-warfarin can be increased when it is combined with Ranitidine.
The serum concentration of (S)-Warfarin can be increased when it is combined with Ranitidine.
2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Ranitidine.
2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Ranitidine.
4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Ranitidine.
The metabolism of 4-Methoxyamphetamine can be decreased when combined with Ranitidine.
The metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Ranitidine.
The metabolism of 6-O-benzylguanine can be decreased when combined with Ranitidine.
The metabolism of 8-azaguanine can be decreased when combined with Ranitidine.
The metabolism of 8-chlorotheophylline can be decreased when combined with Ranitidine.
The metabolism of 9-Deazaguanine can be decreased when combined with Ranitidine.
The metabolism of 9-Methylguanine can be decreased when combined with Ranitidine.
Ranitidine may decrease the excretion rate of Abacavir which could result in a higher serum level.
Ranitidine can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy.
The metabolism of Ranitidine can be increased when combined with Abatacept.
The serum concentration of Abemaciclib can be increased when it is combined with Ranitidine.
The serum concentration of Ranitidine can be increased when it is combined with Abiraterone.
Acarbose may decrease the excretion rate of Ranitidine which could result in a higher serum level.
The serum concentration of Acebutolol can be increased when it is combined with Ranitidine.
Aceclofenac may decrease the excretion rate of Ranitidine which could result in a higher serum level.

References

  • 1 . Mauran A, Goze T, Abadie D, Bondon-Guitton E, Chevrel P, Schmitt L, Montastruc JL, Montastruc F: Mania associated with ranitidine: a case report and review of literature. Fundam Clin Pharmacol. 2016 Aug;30(4):294-6. doi: 10.1111/fcp.12201. Epub 2016 May 5. [PubMed: 27083385]
  • 2 . Grant SM, Langtry HD, Brogden RN: Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989 Jun;37(6):801-70. doi: 10.2165/00003495-198937060-00003. [PubMed: 2667937]
  • 3 . Pettit M: Treatment of gastroesophageal reflux disease. Pharm World Sci. 2005 Dec;27(6):432-5. doi: 10.1007/s11096-005-4798-7. [PubMed: 16341949]
  • 4 . Badillo R, Francis D: Diagnosis and treatment of gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther. 2014 Aug 6;5(3):105-12. doi: 10.4292/wjgpt.v5.i3.105. [PubMed: 25133039]
  • 5 . Sontag S, Robinson M, McCallum RW, Barwick KW, Nardi R: Ranitidine therapy for gastroesophageal reflux disease. Results of a large double-blind trial. Arch Intern Med. 1987 Aug;147(8):1485-91. [PubMed: 3307670]
  • 6 . Vezzadini P, Bonora G, Tomassetti P, Pazzaglia M, Labo G: Medical treatment of Zollinger-Ellison syndrome with ranitidine. Int J Tissue React. 1983;5(4):339-43. [PubMed: 6323334]
  • 7 . Caitlin C. Nugent; Jamie M. Terrell (2018). H2 Blockers- StatPearls. StatPearls Publishing.
  • 8 . FDA drug approval package: Zantac [Link]
  • 9 . Zantac injection FDA label [File]
  • 10 . Zantac Canadian Monograph [File]

Recent Questions